Caption Management’s ADMA Biologics ADMA Stock Holding History

Caption Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.93M	Sell	470,000 -190,000	-29%	-$1.73M	0.02%	653
2026 Q1	$5.95M	Buy	+660,000	New	+$10.4M	0.03%	484
2025 Q4	–	Sell	-195,000	Closed	-$3.29M	–	1524
2025 Q3	$2.86M	Buy	195,000 +87,000	+81%	+$1.49M	0.02%	695
2025 Q2	$1.97M	Buy	+108,000	New	+$2.2M	0.02%	722

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Caption Management's ADMA Position: Q2 2026 in Review

Caption Management reduced its ADMA Biologics (ADMA) stake by 29% in Q2 2026, selling an estimated $1.73M and leaving 470,000 shares worth $3.93M. The position accounts for 0.02% of the portfolio, ranked #653.

Caption Management first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.95M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Caption Management held 470,000 shares of ADMA Biologics worth $3.93M as of Q2 2026.
Caption Management sold 190,000 ADMA Biologics shares in Q2 2026, an estimated $1.73M.
ADMA Biologics made up 0.02% of Caption Management's portfolio in Q2 2026, its #653 holding.
Caption Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
Caption Management's ADMA Biologics position peaked at $5.95M in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.